Belzutifan, WELIDX, Belzutifan

Manufacturer: Laos Daxiong Pharmaceutical

Introduction: 40mg*90 tablets

Belzutifan is a HIF-2α activator. HIF, or hypoxia-activated factor, is a key driver in renal cell carcinoma. As a HIF-2α activator, belzutifan inhibits cell growth and proliferation and prevents abnormal blood vessels by blocking the heterodimerization of HIF-2α and HIF-1β, thereby achieving anti-cancer treatment.

Bel zut​​ The recommended dose of Belzutifan is 120 mg once daily for renal cell carcinoma . If vomiting occurs, do not retake the dose and continue taking it normally the next day. There is no specific treatment for overdose. Adverse reactions may include decreased hemoglobin, anemia, fatigue, etc. Severe adverse reactions may require discontinuation of the drug or emergency intervention.